Won Jun Kang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3404749/publications.pdf

Version: 2024-02-01

		218677	254184
84	2,179	26	43
papers	citations	h-index	g-index
87	87	87	3380
	07	07	3300
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prognostic value of complete metabolic response on 18F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer. Journal of Gynecologic Oncology, 2022, 33, .	2.2	3
2	Serum glucose excretion after Roux-en-Y gastric bypass: a potential target for diabetes treatment. Gut, 2021, 70, 1847-1856.	12.1	19
3	Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer. Annals of Nuclear Medicine, 2021, 35, 415-420.	2.2	3
4	KSNM60 in Cardiology: Regrowth After a Long Pause. Nuclear Medicine and Molecular Imaging, 2021, 55, 151-161.	1.0	0
5	Characteristics of surgically transposed ovaries on 18F-FDG PET/CT among patients with cancer. Annals of Nuclear Medicine, 2021, 35, 1100-1108.	2.2	2
6	Tumor Glucose Metabolism and Its Heterogeneity on F-18 FDG PET/CT Provide Better Prognostication in Nonmetastatic Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma. Cancers, 2021, 13, 5538.	3.7	5
7	Fabrication and evaluation of bilateral Helmholtz radiofrequency coil for thermoâ€stable breast image with reduced artifacts. Journal of Applied Clinical Medical Physics, 2021, 23, e13483.	1.9	3
8	Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma. Nuclear Medicine and Molecular Imaging, 2020, 54, 28-34.	1.0	5
9	Malignant Transformation of an Epidermoid Cyst in an Intrapancreatic Accessory Spleen: A Case Report. Nuclear Medicine and Molecular Imaging, 2020, 54, 58-60.	1.0	2
10	Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer. Pharmaceutics, 2020, 12, 985.	4.5	8
11	Therapeutic Efficacy of Curcumin Enhanced by Microscale Discoidal Polymeric Particles in a Murine Asthma Model. Pharmaceutics, 2020, 12, 739.	4.5	13
12	Early Assessment of Response to Neoadjuvant Chemotherapy with ¹⁸ F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer. Cancer Research and Treatment, 2020, 52, 1211-1218.	3.0	4
13	Biodegradable micro-sized discoidal polymeric particles for lung-targeted delivery system. Biomaterials, 2019, 218, 119331.	11.4	20
14	PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE, 2019, 14, e0211047.	2.5	32
15	Patterns of initially overlooked recurrence of peritoneal lesions in patients with advanced ovarian cancer on postoperative multi-detector row CT. Acta Radiologica, 2019, 60, 1713-1720.	1.1	4
16	Is Chest Computed Tomography Always Necessary Following Nephrectomy for Renal Cell Carcinoma? A Pilot Study in Single Tertiary Institution. Journal of Computer Assisted Tomography, 2019, 43, 333-337.	0.9	2
17	Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET/CT in advanced epithelial ovarian cancer. BMC Cancer, 2018, 18, 1165.	2.6	20
18	Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. Nuclear Medicine and Molecular Imaging, 2018, 52, 445-452.	1.0	2

#	Article	IF	CITATIONS
19	Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer. Molecular Therapy - Nucleic Acids, 2018, 12, 543-553.	5.1	68
20	PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation. Clinical Nuclear Medicine, 2016, 41, 677-682.	1.3	13
21	The diagnostic ability of 18F-FDG PET/CT for mediastinal lymph node staging using 18F-FDG uptake and volumetric CT histogram analysis in non-small cell lung cancer. European Radiology, 2016, 26, 4515-4523.	4.5	24
22	Synergic chemoprevention with dietary carbohydrate restriction and supplementation of AMPK-activating phytochemicals. European Journal of Cancer Prevention, 2016, 25, 54-64.	1.3	11
23	A Comparison Study of Esophageal Findings on 18F-FDG PET/CT and Esophagogastroduodenoscopy. Nuclear Medicine and Molecular Imaging, 2016, 50, 123-129.	1.0	3
24	Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging. Biomaterials, 2016, 100, 143-151.	11.4	23
25	Is there an additive value of 18 F-FDG PET-CT to CT/MRI for detecting nodal metastasis in oropharyngeal squamous cell carcinoma patients with palpably negative neck?. Acta Radiologica, 2016, 57, 1352-1359.	1.1	18
26	Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer. Annals of Nuclear Medicine, 2016, 30, 104-113.	2.2	53
27	Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. European Journal of Radiology, 2015, 84, 2633-2639.	2.6	26
28	⟨sup>18 /sup> <scp>F /scp>â€<scp>FDG PET /scp>CT /scp> as a supplement to <scp>CT /scp>/<scp>MRI /scp> for detection of nodal metastasis in hypopharyngeal <scp>SCC with palpably negative neck. Laryngoscope, 2015, 125, 1607-1612.</scp></scp></scp></scp></scp>	2.0	10
29	F-18 Fluoride Positron Emission Tomography-Computed Tomography for Detecting Atherosclerotic Plaques. Korean Journal of Radiology, 2015, 16, 1257.	3.4	3
30	18F-FDG PET/CT in hepatocellular carcinoma. Nuclear Medicine Communications, 2015, 36, 226-233.	1.1	23
31	Differentiation of an adrenal mass in patients with non-small cell lung cancer by means of a normal range of adrenal standardized uptake values on FDG PET/CT. Annals of Nuclear Medicine, 2015, 29, 276-283.	2.2	11
32	Clinical Usefulness of [18F]FDG PET-CT and CT/MRI for Detecting Nodal Metastasis in Patients with Hypopharyngeal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2015, 22, 994-999.	1.5	8
33	18F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with 18F-FDG and bioluminescence imaging. Nuclear Medicine and Biology, 2015, 42, 728-733.	0.6	4
34	The Performance of Contrast-Enhanced FDG PET/CT for the Differential Diagnosis of Unexpected Ovarian Mass Lesions in Patients With Nongynecologic Cancer. Clinical Nuclear Medicine, 2015, 40, 97-102.	1.3	12
35	Multimodal imaging probe for targeting cancer cells using uMUC-1 aptamer. Colloids and Surfaces B: Biointerfaces, 2015, 136, 134-140.	5.0	20
36	64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model. PLoS ONE, 2015, 10, e0131083.	2.5	6

#	Article	IF	CITATIONS
37	Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Respiratory Research, 2014, 15, 148.	3.6	53
38	18F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy. Annals of Nuclear Medicine, 2014, 28, 304-313.	2.2	23
39	The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1898-1906.	6.4	63
40	Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. Annals of Nuclear Medicine, 2014, 28, 430-435.	2.2	28
41	The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. Nuclear Medicine and Molecular Imaging, 2014, 48, 130-136.	1.0	34
42	Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer. Nuclear Medicine and Molecular Imaging, 2013, 47, 257-262.	1.0	10
43	Radioisotope imaging of microRNA-9-regulating neurogenesis using sodium iodide sympoter. Biomaterials, 2013, 34, 4803-4809.	11.4	7
44	Evaluation of 18F-FDG Excretion Patterns in Malignant Obstructive Uropathy. Clinical Nuclear Medicine, 2013, 38, 695-702.	1.3	5
45	Supraclavicular Lymph Nodes Detected by 18F-FDG PET/CT in Cancer Patients: Assessment With 18F-FDG PET/CT and Sonography. American Journal of Roentgenology, 2012, 198, 187-193.	2.2	14
46	Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 169-175.	1.0	21
47	Dual optical biosensors for imaging microRNA-1 during myogenesis. Biomaterials, 2012, 33, 6430-6437.	11.4	29
48	Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. European Radiology, 2011, 21, 1077-1087.	4.5	23
49	Molecular beacon-based bioimaging of multiple microRNAs during myogenesis. Biomaterials, 2011, 32, 1915-1922.	11.4	90
50	Using 18F-FDG PET/CT to Detect an Occult Mesenchymal Tumor Causing Oncogenic Osteomalacia. Nuclear Medicine and Molecular Imaging, 2011, 45, 233-237.	1.0	10
51	Evaluation of Bone Metastasis from Hepatocellular Carcinoma Using 18F-FDG PET/CT and 99mTc-HDP Bone Scintigraphy: Characteristics of Soft Tissue Formation. Nuclear Medicine and Molecular Imaging, 2011, 45, 203-211.	1.0	13
52	¹⁸ Fâ€fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer, 2011, 117, 4779-4787.	4.1	47
53	The Clinical Utility of Positron Emission Tomography-computed Tomography in the Evaluation of Inflammatory Bowel Diseases. Intestinal Research, 2011, 9, 97-104.	2.6	0
54	Postoperative Functional Outcome After Off-Pump Versus On-Pump Coronary Artery Bypass Grafting Using Gated Myocardial SPECT: A Comparison by Propensity Score Analysis. Nuclear Medicine and Molecular Imaging, 2010, 44, 110-115.	1.0	3

#	Article	IF	Citations
55	Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines. Journal of Nuclear Medicine, 2009, 50, 1525-1532.	5.0	53
56	The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer, 2009, 9, 73.	2.6	81
57	18F-FDG PET/CT in mediastinal lymph node staging of non-small-cell lung cancer in a tuberculosis-endemic country: consideration of lymph node calcification and distribution pattern to improve specificity. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1794-1802.	6.4	66
58	Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdominal Imaging, 2009, 34, 430-440.	2.0	53
59	In vitro Derby Imaging of Cancer Biomarkers Using Quantum Dots. Small, 2009, 5, 1207-1212.	10.0	55
60	Multiplex Imaging of Single Tumor Cells Using Quantumâ€Dotâ€Conjugated Aptamers. Small, 2009, 5, 2519-2522.	10.0	95
61	Bioimaging of geographically adjacent proteins in a single cell by quantum dotâ€based fluorescent resonance energy transfer. Proteomics - Clinical Applications, 2009, 3, 1383-1388.	1.6	23
62	Comparison of maximal elastance and systolic wall thickening using arterial tonometry and gated myocardial SPECT in patients undergoing coronary artery bypass grafting. Applied Radiation and Isotopes, 2009, 67, 1382-1386.	1.5	0
63	Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated 18F-FDG PET/CT. Lung Cancer, 2009, 65, 180-186.	2.0	85
64	Detection of Metastatic Cervical Lymph Nodes in Recurrent Papillary Thyroid Carcinoma. Journal of Computer Assisted Tomography, 2009, 33, 805-810.	0.9	13
65	The clinical impact of [18F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1081-1088.	6.4	69
66	Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Annals of Nuclear Medicine, 2008, 22, 727-734.	2.2	40
67	Primary Cancer of the Liver and Biliary Duct. PET Clinics, 2008, 3, 169-186.	3.0	2
68	Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenetics and Genomics, 2008, 18, 91-97.	1.5	10
69	Analysis of Serum Levels of Anti-Mýllerian Hormone, Inhibin B, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-3, and Follicle-Stimulating Hormone with Respect to Age and Menopausal Status. Journal of Korean Medical Science, 2008, 23, 104.	2.5	30
70	FDG-PET for Evaluating the Antitumor Effect of Intraarterial 3-Bromopyruvate Administration in a Rabbit VX2 Liver Tumor Model. Korean Journal of Radiology, 2007, 8, 216.	3.4	20
71	Development of acetylated HDD kit for preparation of 188Re-HDD/lipiodol. Applied Radiation and Isotopes, 2007, 65, 64-69.	1.5	18
72	Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecologic Oncology, 2007, 104, 529-534.	1.4	121

#	Article	IF	CITATIONS
73	Progressive improvement of myocardial perfusion after off-pump revascularization with bilateral internal thoracic arteries: Comparison of early versus 1-year postoperative myocardial single photon emission computed tomography. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 52-57.	0.8	16
74	Characterization of surgically transposed ovaries in integrated PET/CT scan in patients with cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 88-93.	2.8	9
75	Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 480-486.	6.4	104
76	Frontal Dysfunction Underlies Depressive Syndrome in Alzheimer Disease: A FDG-PET Study. American Journal of Geriatric Psychiatry, 2006, 14, 625-628.	1.2	46
77	An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK). Nuclear Medicine and Biology, 2006, 33, 677-683.	0.6	39
78	High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy. Clinical Cancer Research, 2006, 12, 4232-4236.	7.0	38
79	Time course of functional recovery after coronary artery bypass grafting surgery according to the preoperative reversibility of perfusion impairment on myocardial SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 70-74.	6.4	12
80	Biological properties of 2′-[18F]fluoroflumazenil for central benzodiazepine receptor imaging. Nuclear Medicine and Biology, 2005, 32, 263-268.	0.6	28
81	Diagnostic performance of 18F-FDG PET and ictal 99mTc-HMPAO SPET in pediatric temporal lobe epilepsy: Quantitative analysis by statistical parametric mapping, statistical probabilistic anatomical map, and subtraction ictal SPET. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 213-220.	2.0	58
82	Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 202-207.	6.4	21
83	Dosimetry in leakage of 188 Re-DTPA during intracoronary balloon brachytherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1263-1265.	6.4	5
84	Prognostic value of rest (201)Tl-dipyridamole stress (99m)Tc-sestamibi gated SPECT for predicting patient-based clinical outcomes after bypass surgery in patients with ischemic left ventricular dysfunction. Journal of Nuclear Medicine, 2003, 44, 1735-40.	5.0	13